journal article·2022-02

Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer Immunotherapy

Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou

Advanced Materials· Volume 34· Issue 7
Publisher page

Abstract

Abstract The checkpoint inhibitor therapy that blocks programmed death‐1 (PD‐1) and its major ligand PD‐L1 has achieved encouraging clinical efficacy in certain cancers. However, the binding of checkpoint inhibitors with other immune cells that express PD‐L1 often results in a low response rate to the blockade and severe adverse effects. Herein, an LyP1 polypeptide‐modified outer‐membrane vesicle (LOMV) loaded with a PD‐1 plasmid is developed to achieve self‐blockade of PD‐L1 in tumor cells. The nanocarriers accumulate in the tumor tissue through OMV‐targeting ability and are internalized into the tumor cells via the LyP1‐mediated target, subsequently delivering PD‐1 plasmid into the nucleus, leading to the expression of PD‐1 by the tumor cells. In addition, a magnetic particle chemiluminescence kit is developed to quantitatively detect the binding rate of PD‐1/PD‐L1. The self‐expressed PD‐1 bonded with the PD‐L1 is expressed by both autologous and neighboring tumor cells, achieving self‐blockade. Simultaneously, the outer‐membrane protein of LOMV recruits cytotoxic lymphocyte cells and natural killer cells to tumor tissues and stimulates them to secrete IFN‐γ , improving the antitumor activity of the PD‐1/PD‐L1 self‐blocking therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Advanced Technologies of Materials Ministry of Education School of Materials Science and Engineering Southwest Jiaotong University Chengdu 610031 P. R. China

School of Life Science and Engineering Southwest Jiaotong University Chengdu 610031 P. R. China

Funding

National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1038/nrc323910.1038/nrc3239 ↗
2. 10.1016/j.cell.2017.07.02410.1016/j.cell.2017.07.024 ↗
3. 10.1126/science.aax018210.1126/science.aax0182 ↗
4. 10.1038/ncomms1050110.1038/ncomms10501 ↗
5. 10.1016/S1074-7613(00)80089-810.1016/S1074-7613(00)80089-8 ↗
6. 10.1146/annurev.immunol.26.021607.09033110.1146/annurev.immunol.26.021607.090331 ↗
7. 10.1016/j.it.2006.02.00110.1016/j.it.2006.02.001 ↗
8. 10.1126/science.aar406010.1126/science.aar4060 ↗
9. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
10. 10.1056/NEJMoa100346610.1056/NEJMoa1003466 ↗
11. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
12. 10.1186/2051-1426-1-S1-O2410.1186/2051-1426-1-S1-O24 ↗
13. 10.1016/j.tips.2015.06.00510.1016/j.tips.2015.06.005 ↗
14. 10.1038/s41467-017-01830-810.1038/s41467-017-01830-8 ↗
15. 10.1126/sciimmunol.aau658410.1126/sciimmunol.aau6584 ↗
16. 10.1021/acsnano.6b0815210.1021/acsnano.6b08152 ↗
17. 10.1002/adma.20150631210.1002/adma.201506312 ↗
18. 10.1002/adma.20180332210.1002/adma.201803322 ↗
19. 10.1038/ncomms1249910.1038/ncomms12499 ↗
20. 10.1038/nature1429210.1038/nature14292 ↗
21. 10.1038/ncomms1319310.1038/ncomms13193 ↗
22. 10.1021/acs.nanolett.9b0218210.1021/acs.nanolett.9b02182 ↗
23. 10.1002/advs.20200357210.1002/advs.202003572 ↗
24. 10.1038/s41467-017-00729-810.1038/s41467-017-00729-8 ↗
25. 10.1038/s41579-019-0201-x10.1038/s41579-019-0201-x ↗
26. 10.1038/s41565-019-0589-510.1038/s41565-019-0589-5 ↗
27. 10.1002/adma.20180500710.1002/adma.201805007 ↗
28. 10.1016/S0092-8674(03)00754-210.1016/S0092-8674(03)00754-2 ↗
29. 10.1021/nn405724x10.1021/nn405724x ↗
30. 10.1002/anie.20110450710.1002/anie.201104507 ↗
31. 10.1016/j.bios.2017.08.03210.1016/j.bios.2017.08.032 ↗
32. 10.1038/s41586-018-0392-810.1038/s41586-018-0392-8 ↗
33. 10.1128/JCM.01436-2010.1128/JCM.01436-20 ↗
34. 10.1038/s41598-019-46548-310.1038/s41598-019-46548-3 ↗
35. 10.1021/acsami.8b0587610.1021/acsami.8b05876 ↗
36. 10.1002/smll.20190388110.1002/smll.201903881 ↗
37. 10.1126/sciadv.abb872510.1126/sciadv.abb8725 ↗
38. 10.1016/j.cllc.2018.04.01410.1016/j.cllc.2018.04.014 ↗
39. 10.1093/annonc/mdz19610.1093/annonc/mdz196 ↗
40. 10.1016/j.cell.2016.08.06910.1016/j.cell.2016.08.069 ↗
41. 10.1038/nri160410.1038/nri1604 ↗
42. 10.1016/j.celrep.2017.04.03110.1016/j.celrep.2017.04.031 ↗
43. 10.1016/j.immuni.2018.03.01410.1016/j.immuni.2018.03.014 ↗
44. 10.1021/acsnano.0c0377610.1021/acsnano.0c03776 ↗
45. 10.1016/j.ccell.2019.05.00410.1016/j.ccell.2019.05.004 ↗
46. 10.1002/adfm.20190692210.1002/adfm.201906922 ↗
47. 10.1038/s41467-021-22308-810.1038/s41467-021-22308-8 ↗
48. 10.1038/nri286810.1038/nri2868 ↗
49. 10.1056/NEJMoa120069410.1056/NEJMoa1200694 ↗
50. 10.1056/NEJMoa120069010.1056/NEJMoa1200690 ↗